Replies to post #211723 on Biotech Values

[masterlongevity]

i agree. xtandi is a beter drug

[DewDiligence]

Astellas/PFE terminate Xtandi program in breast cancer (all settings):

Astellas $PFE discontinue all breast cancer trials for Xtandi pic.twitter.com/N9yLfKlz8g

— M (@bio_clouseau) July 28, 2017

[DewDiligence]

PFE/Astellas—Xtandi prolongs MFS in non-metastatic CRPC:

https://finance.yahoo.com/news/pfizer-astellas-announce-positive-top-090000228.html

Pfizer Inc. and Astellas Pharma…announced today that the Phase 3 PROSPER trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS). The preliminary safety analysis of the PROSPER trial appears consistent with the safety profile of XTANDI in previous clinical trials.

…Based on the results of PROSPER, the companies intend to discuss the data with global health authorities to potentially support expanding the label for XTANDI to cover all patients with CRPC.

This is pretty big win from a commercial standpoint.